Novo Nordisk A/S (ETR:NOV)
44.29
+0.50 (1.14%)
Aug 15, 2025, 10:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
4.64
Revenue / Employee
4.03M DKK
Employees
77,349
Market Cap
194.07B EUR
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Sartorius Aktiengesellschaft | 3.47B |
Fresenius Medical Care AG | 19.52B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Novo Nordisk News
- 10 hours ago - Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH - Reuters
- 10 hours ago - Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH - GlobeNewsWire
- 11 hours ago - NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit - PRNewsWire
- 14 hours ago - Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst - Benzinga
- 14 hours ago - DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewsWire
- 15 hours ago - Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes - Barrons
- 15 hours ago - Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO - PRNewsWire
- 18 hours ago - September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO - PRNewsWire